Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Regeneron Pharmaceuticals Inc (REGN) Calls Game, Set and Match On Its Competitor: Jim Cramer

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has, once again, shown today why biopharmaceuticals companies are so popular with investors, especially those with a speculative itch. After the news came out that the company has yet another new drug in its portfolio, Eylea, used for treating diabetic macular edema, or more simply high cholesterol, the stock is up a whooping 9.6% right now, but this could have well been a 18% rise. CNBC‘s Jim Cramer explained why this wasn’t the case.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

In any sport, there are players who show sportmanship and take their defeat in a stride, and then there are sore losers, like Amgen, Inc. (NASDAQ:AMGN) which start to complain with the referee when the match has almost already been won by Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

The referee that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will be dragged to is United States (U.S.) District Court of Delaware. Amgen has also decided to drag Sanofi SA (ADR) (NYSE:SNY), Regeneron’s partner in crime to the court regarding patent infringement. However, the move did little to stop Regeneron Pharmaceuticals Inc (NASDAQ:REGN)’s investors from celebrating and even more people rounded up for their piece of the pie, pushing the stock higher.

Cramer had one word for these sort of lawsuits, messy. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will probably have to wait a little longer before it finally launches its product in the market. Of course, there is also a chance that the cry baby, Amgen, will have to be given some candy, or cash in legal terms, to stop complaining.

 “[…]Yes, definitely. When you have a headway compared with the most important competitor, it’s pretty clear that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is highly a, it’s game set and match for them. The Amgen, Inc. (NASDAQ:AMGN) patent claim, I don’t know, you know how patent claims work, they tend to be messy. I think that Regeneron has and Sanofi , their patent is good and the cholesterol drug is amazing because it works in addition to others where you have sticky cholesterol that will not come down,” said Cramer.

Video Embed Size: 530 X 298 640 X 360

Warren Buffett and BillionairesFree Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW for all the details.